Surgery offers pancreatic cancer patients the best chance for long-term survival, yet currently less than 20% of patients are eligible upon diagnosis. Unfortunately, the majority of pancreatic cancers are identified after the disease has metastasized, or spread to other organs, making treatment more challenging.
But Lustgarten-supported researchers are always up for a challenge. We are committed to funding the world’s best earlier detection research, giving patients and their families more help—and more hope—than ever before.
CancerSEEK, developed by Lustgarten-funded researcher Dr. Bert Vogelstein and his team at Johns Hopkins Kimmel Cancer Center, has been proven to detect the early presence of pancreatic and nine other cancers.
Leveraging artificial intelligence, the FELIX program uses data from thousands of scans to teach computers to detect tumors small enough to be missed by even the most experienced radiologists.
The GENERATE Study is designed to improve genetic testing and cancer prevention in family members of pancreatic cancer patients.